New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
16:25 EDTARIA, PAY, QUAD, ADBE, BBY, RIGL, GEOn The Fly: Closing Wrap
Stocks on Wall Street finished lower after the averages sat just below the flat line for much of the session. Stocks moved lower during the final ninety minutes of trading, leaving each of the major averages down on the week... ECONOMIC EVENTS: In the U.S., a report showed consumer prices declined 0.3% in November, mainly because of falling gasoline costs. When food and energy are removed from the equation, "core" prices increased 0.1%, versus expectations for them to rise 0.2%. Markit's preliminary manufacturing PMI improved to 54.2 in December, versus the 52.8 final reading for November. Industrial production beat expectations with a 1.1% increase in November, versus expectations for a rise of 0.3%. Industrial production capacity utilization rose to 78.4%, which was a bit more than an expected move up to 78.0%. In China, Markit's flash China PMI rose to a 14-month high reading of 50.9, beating expectations for a 50.8 reading. In Europe, Germany's flash PMI hit an 8-month high with a 50.2 reading... COMPANY NEWS: General Electric (GE) boosted its dividend by 12% to 19c per share and increased its existing share repurchase authorization by $10B... Among companies reporting earnings last night, Adobe (ADBE) shares rose $2.05, or 5.77%, to $37.58, while shares of VeriFone (PAY) declined $3.63, or 10.92%, to $29.60... MAJOR MOVERS: Among the notable gainers was Rigel Pharmaceuticals (RIGL), up $1.01, or 18.33%, to $6.52 after Leerink called the recent pullback a "temporary dislocation" and maintained an Outperform rating in the name. Also higher were shares of Quad/Graphics (QUAD), up $2.40, or 14.36%, to $19.11 after the company increased its quarterly dividend by 20% and declared a $2.00 per share special dividend. Among noteworthy losers was Aria Pharmaceuticals (ARIA), down $4.95, or 20.73%, to $18.93 after announcing that its leukemia treatment was approved by the FDA, though the regulator required that the drug include a "Boxed Warning." Shares of Best Buy (BBY) also slid $2.07, or 14.66%, to $12.05 after the company's board extended the deadline for founder Richard Schulze to deliver a potential buy-out bid... INDICES: The Dow was down 35.71, or 0.27%, to 13,135.01; the Nasdaq was down 20.83, or 0.70%, to 2,971.33; the S&P 500 was down 5.87, or 0.41%, to 1,413.58.
News For GE;ADBE;PAY;RIGL;QUAD;ARIA;BBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 11, 2014
16:07 EDTADBEAdobe reports Q4 creative ARR revenue $1.676B
Subscribe for More Information
16:06 EDTADBEAdobe added 644,000 net new creative cloud subscriptions in Q4
Subscribe for More Information
16:05 EDTADBEAdobe reports Q4 adjusted EPS 36c, consensus 30c
Subscribe for More Information
15:13 EDTADBENotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Adobe Systems (ADBE), consensus 30c; Quiksilver (ZQK), consensus (11c); Nordson (NDSN), consensus $1.13; Dominion Diamond (DDC), consensus 27c.
14:59 EDTADBEAdobe December volatility elevated into Q4 and outlook
Adobe December call option implied volatility is at 45, January is at 31, April is at 28; compared to its 26-week average of 29 according to Track Data, suggesting large near term price movement into the expected release of Q4 results today after the market close.
14:43 EDTADBEAdobe technical comments ahead of earnings
Subscribe for More Information
10:13 EDTQUADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:13 EDTARIAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
09:16 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTARIAARIAD downgraded at Credit Suisse
As previously reported, Credit Suisse downgraded ARIAD to Underperform from Neutral. The firm said Iclusig launch metrics are weak and expects it to remain a last option for CML patients with specific resistant mutations or failure with other therapies. Price target lowered to $6 from $8.
06:28 EDTQUADQuad/Graphics initiated with an Outperform at Macquarie
Subscribe for More Information
06:14 EDTARIAARIAD downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
December 10, 2014
08:08 EDTBBYBest Buy field checks show good November, says Jefferies
Subscribe for More Information
08:04 EDTGEGE Energy Financial Services, Pacifico to build second joint solar project
Subscribe for More Information
08:00 EDTADBEAdobe December volatility increases into Q4 and outlook
Adobe December call option implied volatility is at 46, January is at 29, April is at 27; compared to its 26-week average of 29 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on December 11.
December 9, 2014
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
07:24 EDTADBEAdobe December volatility elevated into Q4 and outlook
Subscribe for More Information
December 8, 2014
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use